Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Jobs Report Highlighted During Holiday-Shortened Week Baystreet - Fri Jun 28, 4:49PM CDT

Monday U.S. Economic Lookahead S&P final U.S. manufacturing PMI (June) Construction ...

DDD : 2.95 (-0.67%)
DZSI : 1.1800 (+1.72%)
PXD : 269.62 (+0.73%)
MSM : 80.02 (+2.29%)
SLP : 46.86 (+1.47%)
RDUS : 14.67 (-4.05%)
STZ : 258.94 (+1.03%)
KALV : 11.51 (-3.20%)
U.S. Inflation News Due out Next Week Baystreet - Fri Sep 8, 2023

Monday U.S. Featured Earnings Oracle Corporation (NYSE:ORCL) (Q1) Reported EPS of 90 cents ...

FLOW.TO : 0.1900 (-13.64%)
GRA.TO : 2.51 (+1.62%)
CXI.TO : 26.40 (-0.30%)
ORCL : 143.28 (+0.13%)
CASY : 373.90 (-0.87%)
INNV : 5.03 (-0.20%)
EPM : 5.26 (-1.68%)
TSP : 0.2500 (-5.66%)
CBRL : 40.66 (-0.34%)
REVG : 24.98 (+1.46%)
IBEX : 16.15 (+1.19%)
ADBE : 567.71 (+1.37%)
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop Business Wire - Mon May 8, 2023

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced...

KALV : 11.51 (-3.20%)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Tue May 2, 2023

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate...

KALV : 11.51 (-3.20%)
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop Business Wire - Thu Apr 27, 2023

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 11.51 (-3.20%)
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference Business Wire - Wed Apr 12, 2023

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 11.51 (-3.20%)
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results Business Wire - Thu Mar 9, 2023

KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided...

KALV : 11.51 (-3.20%)
KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Business Wire - Mon Feb 27, 2023

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented...

KALV : 11.51 (-3.20%)
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology Business Wire - Thu Feb 16, 2023

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 11.51 (-3.20%)
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development Business Wire - Tue Feb 14, 2023

KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided...

KALV : 11.51 (-3.20%)

Barchart Exclusives

Is This Copper Mining Stock a Buy for Its Fat Dividend? Barchart - Tue Jul 2, 6:30PM CDT
Southern Copper has a higher dividend yield compared to other copper mining companies. However, its valuations are also on the higher side, making a closer examination of the risk-reward necessary for prospective investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot